Wednesday, 7 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange

Dr. Reddy's Laboratories Ltd

NSE: DRREDDY · BSE: 500124 · Pharmaceuticals & Biotechnology · 45 announcements

Dr. Reddy's Laboratories Ltd news stories on ALFA NewsRead the news →
Share price
₹1,198.10
Market cap
₹1,00,003 Cr
Revenue (annual)
₹33,700 Cr
Net profit (annual)
₹4,196 Cr
P/E (TTM)
31.0×Sector 47.4×
Promoter holding
26.64%+0.01% QoQ
FII holding
20.67%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

09:08 IST BSE
Regulatory Approval

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received a Notice of Compliance from Health Canada for its generic Semaglutide Injection. This approval authorizes the company to commercialize and distribute the product in Canada, marking a significant milestone in its GLP-1 therapy portfolio. Launch preparations for 2 mg and 4 mg pens are currently underway.